Glycomacropeptide (GMP) rescued the oxidative and inflammatory activity of free L-AAs in human Caco-2 cells : New insights that support GMP as a valid and health-promoting product for the dietary management of phenylketonuria (PKU) patients
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
Phenylketonuria represents the most prevalent inborn error of amino acid metabolism. In early diagnosed patients adequate and continued dietary treatment results in a good neurologic outcome. However, due to the natural protein and phenylalanine-restricted diet, oxidative stress represents a concern in phenylketonuric patients. Clear evidences suggest that the pathophysiology of PKU is also dependent by mitochondrial impairment and oxidative stress. In this context due to the tight connection between oxidative and inflammatory stress and noncommunicable diseases (NCDs) development, it is reasonable to hypothesize that PKU patients may present a higher risk to develop NCDs during their life. Currently available protein substitutes on the market include free amino acids (L-AAs), prolonged-release protein substitute and formula containing glycomacropeptide (GMP). Our results suggest that free L-AAs significanlty worsens the intestinal hydrogen peroxide (H2O2) and lipopolysaccharides (LPS)-induced oxidative and inflammatory status in Caco-2 cells, which are significantly restored towards physiological condition by GMP alone and when present in a 1:1 mixture with free L-AAs, providing new preclinical piece of information which can shed a shadow on the mechanism of action of these products on PKU patients and their future management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:173 |
|---|---|
| Enthalten in: |
Food research international (Ottawa, Ont.) - 173(2023), Pt 1 vom: 06. Nov., Seite 113258 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lammi, Carmen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BBX060AN9V |
|---|
| Anmerkungen: |
Date Completed 09.10.2023 Date Revised 18.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.foodres.2023.113258 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362971633 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362971633 | ||
| 003 | DE-627 | ||
| 005 | 20231226092345.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.foodres.2023.113258 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362971633 | ||
| 035 | |a (NLM)37803570 | ||
| 035 | |a (PII)S0963-9969(23)00803-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lammi, Carmen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Glycomacropeptide (GMP) rescued the oxidative and inflammatory activity of free L-AAs in human Caco-2 cells |b New insights that support GMP as a valid and health-promoting product for the dietary management of phenylketonuria (PKU) patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.10.2023 | ||
| 500 | |a Date Revised 18.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Phenylketonuria represents the most prevalent inborn error of amino acid metabolism. In early diagnosed patients adequate and continued dietary treatment results in a good neurologic outcome. However, due to the natural protein and phenylalanine-restricted diet, oxidative stress represents a concern in phenylketonuric patients. Clear evidences suggest that the pathophysiology of PKU is also dependent by mitochondrial impairment and oxidative stress. In this context due to the tight connection between oxidative and inflammatory stress and noncommunicable diseases (NCDs) development, it is reasonable to hypothesize that PKU patients may present a higher risk to develop NCDs during their life. Currently available protein substitutes on the market include free amino acids (L-AAs), prolonged-release protein substitute and formula containing glycomacropeptide (GMP). Our results suggest that free L-AAs significanlty worsens the intestinal hydrogen peroxide (H2O2) and lipopolysaccharides (LPS)-induced oxidative and inflammatory status in Caco-2 cells, which are significantly restored towards physiological condition by GMP alone and when present in a 1:1 mixture with free L-AAs, providing new preclinical piece of information which can shed a shadow on the mechanism of action of these products on PKU patients and their future management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Caco-2 cells | |
| 650 | 4 | |a Glycomacropeptide | |
| 650 | 4 | |a Non-communicable diseases | |
| 650 | 4 | |a Phenylketonuria | |
| 650 | 7 | |a caseinomacropeptide |2 NLM | |
| 650 | 7 | |a Hydrogen Peroxide |2 NLM | |
| 650 | 7 | |a BBX060AN9V |2 NLM | |
| 650 | 7 | |a Caseins |2 NLM | |
| 700 | 1 | |a Bollati, Carlotta |e verfasserin |4 aut | |
| 700 | 1 | |a Fiori, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jianqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Fanzaga, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a d'Adduzio, Lorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Tosi, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Burlina, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Zuccotti, Gianvincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Verduci, Elvira |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Food research international (Ottawa, Ont.) |d 1997 |g 173(2023), Pt 1 vom: 06. Nov., Seite 113258 |w (DE-627)NLM091648246 |x 1873-7145 |7 nnns |
| 773 | 1 | 8 | |g volume:173 |g year:2023 |g number:Pt 1 |g day:06 |g month:11 |g pages:113258 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.foodres.2023.113258 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 173 |j 2023 |e Pt 1 |b 06 |c 11 |h 113258 | ||